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syndrome: a true neutrophilic maturation
arrest variant
Histiocytoid Sweet’s syndrome is a recently described entity which
has clinical features identical to typical Sweet’s syndrome but is
distinguished by a dermal cellular infiltrate composed not of mature
neutrophils but of immature granulocytes. Herein, we report a case of
bone marrow granulocytic maturation arrest and a histological
histiocytoid Sweet’s-like reaction pattern following trimethoprim-
sulfamethoxazole therapy.
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Acute febrile neutrophilic dermatosis or Sweet’s
syndrome, is a reactive condition of unknown
etiology characterized by an abrupt onset of tender,
erythematous or violaceous sharply marginated
plaques and nodules, occasionally associated with
pseudovesiculation or pustules. Lesions are asym-
metrically distributed over the face, neck and limbs.
Associated secondary features include clinical
symptoms such as fever and characteristic labora-
tory values including neutrophilic leukocytosis,
elevated erythrocyte sedimentation rate and posi-
tive C-reactive protein. The classic histomorphol-
ogy of Sweet’s syndrome is one of a dichotomous
reaction pattern comprising striking interstitial
neutrophilia accompanied by a mononuclear cell
vascular reaction typically without mural and or
luminal fibrin deposition. The mononuclear cells
may be of monocytic or lymphoid derivation. An
underlying systemic disorder, most often a viral or
streptococcal infection or inflammatory condition
such as inflammatory bowel disease, is found in
approximately 50% of cases. Approximately 10–
20% of cases are associated with hematologic or
solid malignancies.1,2
Recently, Requena et al. described a series of 41
patients who presented with typical cutaneous
lesions of Sweet’s syndrome. Histologically, these
lesions had the architectural features of Sweet’s
syndrome, but the cellular infiltrate was composed
predominantly of immature myeloid precursors
without the morphologic features of either blasts
or segmented neutrophils. Requena et al. held that
the granulocytic nature of the cells was supported
by the phenotypic profile, namely, one comprising
CD68, lysozyme and myeloperoxidase (MPO) posi-
tivity. However, it should be emphasized that while
MPO activity is most pronounced in immature
granulocytes, it is discernible in monocytes as well. A
truly confirmatory marker of granulocytic deriva-
tion, namely that of chloroacetate esterase, along
with negativity for a monocyte-specific marker, such
as a non-specific esterase stain using alpha naphthyl
acetate and alpha naphthyl butyrate was not per-
formed. Because of the morphologic resemblance of
these immature myeloid precursors to histiocytes,
this dermatosis was coined histiocytoid Sweet’s
syndrome.2
In this case report, we present an unusual case of
histiocytoid Sweet’s-like reaction and granulocytic
maturation arrest in a 44-year-old woman following
a course of trimethoprim-sulfamethoxazole (TMP-
SFX) therapy for treatment of sinusitis.
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Clinical presentation
This patient was a 44-year-old previously healthy
woman who presented to her primary care physi-
cian with complaints of sinusitis; a 10-day course of
TMP-SFX was prescribed. Five days into the
antibiotic course, the patient developed myalgia
and fever for 2 days. These symptoms improved,
but approximately 1 week later, she noticed an
erythematous nodule over her left ribcage and
again developed fever and myalgia. Over the next
few days, this nodule grew, developed vesicles and
became painful. Her primary care physician
suspected a spider bite and prescribed a dose of
cephalexin and ceftriaxone. On routine laboratory
tests, the patient was found to have a low white
blood cell (WBC) count; she was informed of
these results and directed to go to the Emergency
Department.
Physical examination and laboratory values
On presentation, the patient had a fever of 101.3 F,
blood pressure 118/78 mmHg, heart rate 106 bpm
and respiratory rate 20 rpm. Physical examination
showed a 1.5-cm hemorrhagic nodule on the left
flank with pseudovesiculation and surrounding ery-
thema measuring approximately 10 cm in diameter
(Fig. 1). This lesion was somewhat tender to pal-
pation. No other skin or oral lesions were present.
Laboratory values were as follows: WBC count
1,200 mm3, hemoglobin 12.3 g/dl, hematocrit
35.9%, platelets 359,000 mm3; absolute neutrophil
count (ANC) 0 mm3, absolute lymphocyte count
1,000 mm3, absolute monocyte count 300 mm3. A
peripheral blood smear review showed no blasts, no
neutrophils and rare band neutrophils. A dermatol-
ogy and hematology consult were obtained. The
patient subsequently underwent skin and bone
marrow biopsies. The differential diagnosis included
an atypical presentation of Sweet’s syndrome
secondary to TMP-SMX, leukemia cutis, arthropod
bite reaction, atypical pyogenic granuloma and an
infectious process.
Histopathology
A biopsy of the juicy, erythematous nodule showed
reticular degeneration of the epidermis with sub-
epidermal edema and a dense band-like mixed
cellular infiltrate centered in the papillary dermis
with extension into the deep dermis and focally into
the superficial subcutis (Fig. 2). The cellular infiltrate
consisted of a small number of mature neutrophils,
many immature cells that spanned the spectrum of
myeloid differentiation, histiocytes and lymphocytes.
A smaller proportion of the immature myeloid cells
were morphologically consistent with myelocytes,
with round nuclei which occupied half the cell; the
majority of the immature precursors were morpho-
logically consistent with metamyelocytes, with reni-
form or folded nuclei with inconspicuous nucleoli
and a nuclear to cytoplasmic ratio of 1 : 3. Both the
myelocytes and metamyelocytes had a moderate
amount of eosinophilic cytoplasm. These precursor
cells were not morphologically consistent with blasts
and showed clear evidence of maturation to a small
number of mature multilobated neutrophils (Fig. 3).
Immunostains showed that these immature cells
were positive for CD68 (KP1), lysozyme, CD45Ro
(A6) and most importantly, MPO (Fig. 2); a subset of
these cells was also positive for CD15 (Leu-M1). No
positive staining for CD34 was observed. Scattered
histiocytes were CD68-positive and lysozyme- and
MPO-negative. The lymphocytes were predomi-
nantly CD3-positive T cells with only rare CD20-
positive B cells. No bacteria, fungi or acid-fast bacilli
were seen in Brown-Hopps tissue gram, Gomori
methenamine silver (GMS) or Fite stains, respec-
tively. No tissue culture from the skin lesion was
obtained. Scrapings of the skin lesion were sub-
mitted for direct fluorescent antibody testing for
herpes simplex and varicella-zoster viruses, which
were negative.
A bone marrow biopsy, that was obtained 4 days
prior to the skin biopsy, showed a 40–50% cellular
marrow with all three cell lines present. A marked
granulocytic predominance with left shift, because of
lack of maturation to segmented neutrophils,
consistent with a granulocytic maturation arrest
was observed. A 300-cell differential count showed
no increase in blasts (0.3%), a relative increase in
promyelocytes (47.7%) and decrease in other
granulocytic precursors and neutrophils (2.7%).
Fig. 1. The patient had a 1.5-cm hemorrhagic nodule over her left
flank with surrounding pseudovesiculation and erythema measuring
approximately 10 cm in diameter.
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The promyelocytes and other granulocytic precur-
sors were morphologically unremarkable. A cyto-
megalovirus viral culture of the bone marrow was
negative.
Flow cytometric analysis of the bone marrow aspi-
rate was phenotypically consistent with maturation
arrest and showed no evidence of leukemia. Cyto-
genetic analysis of the bone marrow showed a normal
female karyotype. Interphase fluorescence in situ hy-
bridization analysis showed no evidence for the
promyelocytic leukemia/retinoic acid receptor-alpha
fusion associated with acute promyelocytic leukemia.
Follow up
The patient became afebrile and her WBC and
ANC counts recovered with intravenous antibiotics
for a presumed infection over the course of her
2-day admission (WBC 6,200 mm3 and ANC
2,500 mm3 at discharge). No topical or systemic
corticosteroid therapy was given. She was dis-
charged with a course of prophylactic Levofloxacin.
At follow-up appointments, 1 week and 1 month
after discharge, the erythematous nodule was noted
to have spontaneously regressed.
Discussion
In the series reported by Requena et al. 41 patients
with histiocytoid Sweet’s syndrome were described.
Associated underlying systemic diseases were present
in only 11 patients, the majority of which were
hematologic malignancies/disorders [chronic mono-
cytic leukemia, lymphoma (not further specified),
monoclonal gammopathy of uncertain significance,
chronic B lymphocytic leukemia and multiple
myeloma]. Two patients had associated solid
malignancies (renal carcinoma and breast carci-
noma). One patient was on immunosuppression for
colitis ulcerosa. In none of these patients was
histiocytoid Sweet’s syndrome linked to a particular
medication or to maturation arrest in the bone
marrow. In this series, the authors proposed that
histiocytoid Sweet’s syndrome was an early stage of
Sweet’s syndrome. They speculated that the cellular
infiltrate in these lesions would later evolve into
Fig. 2. Histopathologic features of the patient’s skin biopsy. A) Low-power view shows a dense band-like cellular infiltrate centered in the
papillary dermis with extension into the deep dermis and superficial subcutis (34, hematoxylin and eosin). B) The infiltrate was composed
primarily of immature myeloid cells. These cells were positive for CD68, C), lysozyme D) and myeloperoxidase (MPO) E) (B–E, 340).
Fig. 3. The dermal cellular infiltrate was composed primarily of
cells with folded nuclei, inconspicuous nucleoli and moderate
eosinophilic cytoplasm; these cells were morphologically consistent
with immature myeloid precursors (3100, oil immersion).
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mature, segmented neutrophils of typical Sweet’s
syndrome.2
This case is unusual in that the histiocytoid
Sweet’s-like reaction in the skin and maturation
arrest of the bone marrow occurred after TMP-SFX
therapy. Although a spider bite was suspected
clinically, the temporal association of this skin lesion
with exposure to TMP-SFX, resolution of the skin
lesion with cessation of the medication, lack of
central ulceration of the lesion and failure of the
patient to recall an arthropod bite at the site did not
support this diagnosis. In order to definitively
establish a drug-associated etiology for this process,
however, it would be necessary to rechallenge the
patient with the agent to see if the same response
occurs; this was not undertaken as a result of the
severity of the initial reaction and because this is
a well described although uncommon complication
of this medication. An atypical presentation of
cutaneous infection was also considered; however,
lack of viral inclusions and negative direct fluores-
cence antibody assays of epithelial cells for herpes
antigen and for varicella-zoster antigen ruled out an
atypical herpes virus infection, and no bacteria,
fungal elements or acid-fast bacilli were identified in
Brown-Hopps tissue gram, GMS and Fite stains,
respectively. Extramedullary hematopoiesis was con-
sidered as well. However, the clinical presentation,
which included fever, as well as the lack of a mixed
cellular infiltrate including erythroid precursors
and/or megakaryocytes argued against this etiology.
There are two possible pathogenic explanations
for the skin lesion in this patient. First, the TMP-
SFX therapy may have independently caused both
granulocytic maturation arrest and the skin lesion
with features of histiocytoid Sweet’s-like reaction.
Various hematologic adverse effects because of
TMP-SFX are rare but well documented and
include anemia, thrombocytopenia and granulocy-
topenia ranging from mild to life threatening.3 The
pathogenesis of non-chemotherapy drug-induced
agranulocytosis is not well understood. Theories
include immune/allergic mechanisms, such as the
formation of anti-neutrophil antibodies and toxic
mechanisms such as direct toxicity of drug metab-
olites against granulocytes. The idiosyncratic nature
of these hematologic side effects is probably because
of genetic polymorphism.4 Drug-induced Sweet’s
syndrome following TMP-SFX therapy has been
reported but is rare. In contrast to our case, all
previous reports of TMP-SFX-associated Sweet’s
syndrome lacked neutropenia because of a granulo-
cytic maturation arrest. Although the pathogenesis
of drug-induced Sweet’s syndrome is poorly under-
stood, it has been proposed that certain drugs may
cause a rise in endogenous levels of granulocyte
colony stimulating factor (G-CSF).5
The second pathogenic explanation for the
cutaneous lesion in this patient is that TMP-SFX
caused an idiosyncratic granulocytic maturation
arrest in the bone marrow. During the recovery
phase from this acute bone marrow insult, elevated
endogenous levels of G-CSF resulted in release of
myeloid precursors from the bone marrow into the
skin resulting in a solitary lesion of histiocytoid
Sweet’s-like reaction in response to an unidentified
local stimulus.
G-CSF is a cytokine that is critical in granulocytic
mobilization and expansion, differentiation to seg-
mented neutrophils and neutrophilic survival. In
healthy1 individuals, low levels of G-CSF maintain
neutrophilic homeostasis.6–8 The level of endoge-
nous G-CSF increases during episodes of stress or
neutropenia and thus is thought to play a key role in
bone marrow neutrophilic recovery.9
G-CSF, both endogenous and exogenous, has
been a commonly implicated mechanism for Sweet’s
syndrome. Levels of endogenous G-CSF have been
found to be significantly higher in patients with
active Sweet’s syndrome than in patients with
inactive Sweet’s syndrome.6 In addition, there has
been several case reports of exogenous G-CSF-
associated Sweet’s syndrome.10–16 Notably, one case
report of G-CSF-induced Sweet’s syndrome de-
scribed a skin biopsy in which the infiltrate had
a number of immature neutrophil precursors.16 The
pathogenesis of G-CSF-induced Sweet’s syndrome
is poorly understood, but one theory is that the
G-CSF-stimulated neutrophils released during neu-
trophilic recovery are functionally abnormal. These
neutrophils may be primed for pathologic initia-
tion of respiratory burst activity and release of
neutrophilic enzymes, leading to tissue and vessel
wall damage. In addition, abnormal expression of
adhesion molecules by these neutrophils may lead to
endothelial adhesion and dermal chemotaxis. Alter-
natively, circulating secondary cytokines, such as
interleukin 6 or tumor necrosis factor a may play
a role in pathological activation of these neutro-
phils.17–19
In conclusion, we present a novel case of a solitary
nodule presenting with a histiocytoid Sweet’s-like
tissue reaction pattern following granulocytic mat-
uration arrest because of TMP-SFX. In correlating
the biopsy result with the clinical appearance of the
skin lesion, the dermatologist’s diagnosis was
a solitary, atypical Sweet’s lesion. Knowledge of
the association between a histiocytoid Sweet’s-like
reaction pattern and TMP-SFX and careful study of
the cytomorphologic features of the cellular infiltrate
may be important in preventing an erroneous
diagnosis of myelodysplastic- or leukemia-associated
Sweet’s syndrome and potential overtreatment of the
patients. In the future, further delineation of specific
Drug-associated histiocytoid Sweet’s syndrome
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clinical and laboratory characteristics associated
with this form of Sweet’s-like reaction would be
helpful in clarifying the underlying pathogenetic
mechanism involved in this process.
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